Hsa-miR-21-5p is induced by interleukin-6 and affects multiple pathogenic factors associated with fibroblast-like synoviocytes in rheumatoid arthritis

Hsa-miR-21-5p 由白细胞介素-6 诱导,并影响类风湿性关节炎中与成纤维细胞样滑膜细胞相关的多种致病因子。

阅读:2
作者:Kei Araki #,Sho Mokuda #,Hiroki Kohno,Naoya Oka,Hirofumi Watanabe,Michinori Ishitoku,Tomohiro Sugimoto,Yusuke Yoshida,Junya Masumoto,Shintaro Hirata

Abstract

Fibroblast-like synoviocytes (FLS) contribute significantly to the pathogenesis of rheumatoid arthritis (RA), particularly through their roles in synovitis and joint destruction. The microRNAs (miRNAs) are short non-coding RNA that regulate gene expression post-transcriptionally. Although more than 2000 human miRNAs are registered, comprehensive analyses of miRNA expression in FLS are limited. Herein, we investigated the relationship between miRNAs and FLS. Next-generation sequencing (small RNA-seq) was performed on primary cultured FLS derived from patients with RA to analyze the mature miRNA expression pattern. To assess inflammation-induced changes in miRNA levels, FLS were cultured with cytokines and evaluated by RT-qPCR. MiRNA mimics were transfected into FLS and an immortalized synovial fibroblast cell line (MH7A cells), and validated using conventional RNA-seq. Out of 2861 mature miRNAs, 297 mature miRNAs were detected and intronic miRNAs were predominated. Notably, hsa-miR-21-5p was abundantly expressed and its expression was enhanced by IL-6 stimulation. The induction of miR-21-5p mimic decreased the expression of Programmed Cell Death 4 (PDCD4) and Osteoprotegerin (OPG), while upregulating Semaphorin 5A (SEMA5A). MiR-21-5p mimic led to enhanced cell proliferation. These data suggest that hsa-miR-21-5p in FLS may exacerbate the pathophysiology of rheumatoid synovitis by promoting FLS proliferation, highlighting its potential as a therapeutic target in RA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。